- Home
- MXCT vs TNGX Comparison
MXCT vs TNGX Comparison
Compare MXCT & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MXCT
- TNGX
- Stock Information
- Founded
- MXCT 1999
- TNGX 2014
- Country
- MXCT United States
- TNGX United States
- Employees
- MXCT N/A
- TNGX N/A
- Industry
- MXCT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- MXCT Health Care
- TNGX Health Care
- Exchange
- MXCT Nasdaq
- TNGX Nasdaq
- Market Cap
- MXCT 239.2M
- TNGX 248.2M
- IPO Year
- MXCT 2021
- TNGX N/A
- Fundamental
- Price
- MXCT $2.15
- TNGX $3.51
- Analyst Decision
- MXCT Strong Buy
- TNGX Strong Buy
- Analyst Count
- MXCT 1
- TNGX 6
- Target Price
- MXCT $9.00
- TNGX $12.20
- AVG Volume (30 Days)
- MXCT 1.3M
- TNGX 4.5M
- Earning Date
- MXCT 08-05-2025
- TNGX 05-12-2025
- Dividend Yield
- MXCT N/A
- TNGX N/A
- EPS Growth
- MXCT N/A
- TNGX N/A
- EPS
- MXCT N/A
- TNGX N/A
- Revenue
- MXCT $37,675,000.00
- TNGX $40,990,000.00
- Revenue This Year
- MXCT $8.82
- TNGX N/A
- Revenue Next Year
- MXCT $21.12
- TNGX N/A
- P/E Ratio
- MXCT N/A
- TNGX N/A
- Revenue Growth
- MXCT N/A
- TNGX 10.09
- 52 Week Low
- MXCT $2.10
- TNGX $1.03
- 52 Week High
- MXCT $5.26
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- MXCT 39.58
- TNGX 78.42
- Support Level
- MXCT $2.20
- TNGX $2.12
- Resistance Level
- MXCT $2.40
- TNGX $3.68
- Average True Range (ATR)
- MXCT 0.13
- TNGX 0.54
- MACD
- MXCT 0.02
- TNGX 0.18
- Stochastic Oscillator
- MXCT 7.41
- TNGX 92.54
About MXCT MaxCyte Inc.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.